Current and Emerging Trends in Patent Law: Cases to Know and Cases to Watch
Fitch, Even, Tabin & Flannery LLP will hold a complimentary webinar, “Current and Emerging Trends in Patent Law: Cases to Know and Cases to Watch,” presented by Joseph F. Marinelli and Eric L. Broxterman. The webinar will take place on Thursday, Oct. 29, 2015, at 9 am PDT / 10:00 am MDT / 11:00 am CDT / 12:00 noon EDT.
In a release, the firm said the patent landscape is constantly changing. This webinar will help you stay informed on recent significant judicial developments in patent law, in both litigation and prosecution, and will provide a preview of Federal Circuit decisions on the horizon for the last quarter of 2015 and into 2016.
The webinar will cover these topics and more:
• Patent-eligible subject matter under Alice—DDR Holdings, LLC v. Hotels.com
• The Supreme Court’s new claim indefiniteness standard in Nautilus—Dow Chemical Co. v. NOVA Chemicals Corp.
• Expert apportionment method for proving damages by reasonable royalty—Summit 6 v. Samsung
• Standards for injunctive relief—Apple v. Samsung
• Good-faith belief of invalidity as a defense to inducement—Commil USA v. Cisco Systems
• Appellate standard for claim construction—TEVA Pharmaceuticals v. Sandoz
• Patent exhaustion based on foreign sales—Lexmark v. Impression
• Approval of biosimilars—Amgen v. Sandoz
Speakers will be Fitch Even partners Joseph F. Marinelli and Eric L. Broxterman. Marinelli has a diverse intellectual property law practice covering all aspects of IP creation, management, enforcement, and licensing, with a particular emphasis on complex litigation. Broxterman is a litigator with extensive trial experience in patent cases and a registered patent attorney who also counsels clients on patent prosecution, infringement/invalidity opinions, and IP transactional issues.
CLE credit has been approved for California and Illinois and is pending in Nebraska. Other states may also award CLE credit upon attendee request. There is no fee to attend, but registration is required.